LENZ Therapeutics files Form 8-K
LENZ Therapeutics filed a Form 8-K on October 28.
Related stories
MicroVision Reports Q3 Revenue of $2.4 Million, Reiterates 2026 Guidance
MicroVision reported a 50% gross margin and a net loss of $12.2 million, or $0.45 per share. It expects 2027 revenue to at least double from 2026 and plans to reduce operating cash
M impact | EQUITY | Oct 29, 2026, 01:05 PM UTC
Deepgram to Acquire Daily, Makers of Pipecat
Deepgram says the acquisition will support a complete, production-ready open stack for conversational voice AI. The company will also introduce the Real-Time Context Standard at it
M impact | EQUITY | Oct 29, 2026, 01:04 PM UTC
Upbound Group Reports Q3 2026 Revenue of $1.15 Billion, Adjusted EPS of $1.01
Revenue exceeded the FactSet consensus estimate of $1.12 billion, and adjusted EPS outperformed the $0.91 estimate. Upbound projected Q4 2026 revenue of $1.15 billion to $1.25 bill
M impact | EQUITY | Oct 29, 2026, 01:04 PM UTC
First Northwest Bancorp Reports Q3 2026 Net Loss of $743,000
The bank holding company reported a loss of $0.08 per basic and diluted share, versus net income of $308,000 in Q2 2026 and $802,000 in Q3 2025. Net interest margin was 2.96%.
M impact | EQUITY | Oct 29, 2026, 01:04 PM UTC
DeFi Development Sets Nov. 12 Date for Q3 2026 Results
The company plans to publish its financial results and business outlook at approximately 8:00 a.m. Eastern Time on its investor relations website.
M impact | EQUITY | Oct 29, 2026, 01:04 PM UTC
Butterfly Network Reports Q3 2026 Results, Exceeding Revenue and EBITDA Guidance
Butterfly Network reported revenue of $32.6 million, above the FactSet consensus estimate of $28.4 million. Adjusted loss was $0.01 per share versus an analyst estimate of $0.04 lo
M impact | EQUITY | Oct 29, 2026, 01:04 PM UTC